The “Growing” Reality of the Neurological Complications of Global “Stem Cell Tourism”

Abstract

“Stem cell tourism” is defined as the unethical practice of offering unproven cellular preparations to patients suffering from various medical conditions. This phenomenon is rising in the field of neurology as patients are requesting information and opportunities for treatment with stem cells for incurable conditions such as multiple sclerosis and amyotrophic lateral sclerosis, despite their clinical research and experimental designation. Here, we review the recent trends in “stem cell tourism” in both the United States and abroad, and discuss the recent reports of neurological complications from these activities. Finally, we frame critical questions for the field of neurology regarding training in the ethical, legal, and societal issues of the global “stem cell tourism,” as well as suggest strategies to alleviate this problem. Although there are ongoing legitimate clinical trials with stem cells for neurological diseases, procedures offered by “stem cell clinics” cannot be defined as clinical research. They lack the experimental and state-of-the-art framework defined by peers and the FDA that focus on human research that safeguard the protection of human subjects against economical exploitation, unwanted side effects, and futility of unproven procedures. “Stem cell tourism” ultimately exploits therapeutic hope of patients and families with incurable neurological diseases and can put in danger the legitimacy of stem cell research as a whole. We posit that an improvement in education, regulation, legislation, and involvement of authorities in global health in neurology and neurosurgery is required.

Keywords

stem cell research - organoids - iPSCs - brain tumors - stem cell tourism - neural stem cells - ALS - MS

• References

• 1 Sasai Y. Next-generation regenerative medicine: organogenesis from stem cells in 3D culture. Cell Stem Cell 2013; 12 (05) 520-530
• 2 Bowman M, Racke M, Kissel J, Imitola J. Responsibilities of health care professionals in counseling and educating patients with incurable neurological diseases regarding “stem cell tourism”: caveat emptor. JAMA Neurol 2015; 72 (11) 1342-1345
• 3 Turner L, Knoepfler P. Selling stem cells in the USA: assessing the direct-to-consumer industry. Cell Stem Cell 2016; 19 (02) 154-157
• 4 Murdoch CE, Scott CT. Stem cell tourism and the power of hope. Am J Bioeth 2010; 10 (05) 16-23
• 5 Devereaux M, Loring JF. Growth of an industry: how U.S. scientists and clinicians have enabled stem cell tourism. Am J Bioeth 2010; 10 (05) 45-46
• 6 Trounson A, McDonald C. Stem cell therapies in clinical trials: progress and challenges. Cell Stem Cell 2015; 17 (01) 11-22
• 7 Al-Tawfiq JA, Banda RW, Ghandour J. Sterile cyst formation after intrathecal stem cell transplant for Parkinson's disease: a case presentation and literature review. J Infect Public Health 2015; 8 (04) 382-385
• 8 Regenberg AC, Hutchinson LA, Schanker B, Mathews DJ. Medicine on the fringe: stem cell-based interventions in advance of evidence. Stem Cells 2009; 27 (09) 2312-2319
• 9 Martell K, Trounson A, Baum E. Stem cell therapies in clinical trials: workshop on best practices and the need for harmonization. Cell Stem Cell 2010; 7 (04) 451-454
• 10 Alderazi YJ, Coons SW, Chapman K. Catastrophic demyelinating encephalomyelitis after intrathecal and intravenous stem cell transplantation in a patient with multiple sclerosis. J Child Neurol 2012; 27 (05) 632-635
• 11 Viswanathan S, Rao M, Keating A, Srivastava A. Overcoming challenges to initiating cell therapy clinical trials in rapidly developing countries: India as a model. Stem Cells Transl Med 2013; 2 (08) 607-613
• 12 Cyranoski D. Korean deaths spark inquiry. Nature 2010; 468 (7323): 485
• 13 Cyranoski D. China's stem-cell rules go unheeded. Nature 2012; 484 (7393): 149-150
• 14 Sipp D. Conditional approval: Japan lowers the bar for regenerative medicine products. Cell Stem Cell 2015; 16 (04) 353-356
• 15 California Legistative Information. SB 512 Health care practitioners: stem cell therapy (2017-18). Available at: https://leginfo.legislature.ca.gov . Accessed October 16, 2017
• 16 Berkowitz AL, Miller MB, Mir SA. , et al. Glioproliferative lesion of the spinal cord as a complication of “stem-cell tourism.”. N Engl J Med 2016; 375 (02) 196-198
• 17 Amariglio N, Hirshberg A, Scheithauer BW. , et al. Donor-derived brain tumor following neural stem cell transplantation in an ataxia telangiectasia patient. PLoS Med 2009; 6 (02) e1000029
• 18 Chen KS, Sakowski SA, Feldman EL. Intraspinal stem cell transplantation for amyotrophic lateral sclerosis. Ann Neurol 2016; 79 (03) 342-353